Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -4.22% is 87% above its 5-year average of -32.27%, near the high end of its 5-year range (-60.29%–-3.04%).
84.55% above its 12-month average of -27.32%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 5.65%.
RETURN ON ASSETS (ROA)
-4.22%
RETURN ON ASSETS (ROA) AVG TTM
-27.32%
RETURN ON ASSETS (ROA) AVG 3Y
-24.76%
RETURN ON ASSETS (ROA) AVG 5Y
-32.27%
RETURN ON ASSETS (ROA) AVG 10Y
-29.41%
RETURN ON ASSETS (ROA) AVG 15Y
-21.29%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+84.55%
CURRENT VS 3Y AVG
+82.96%
CURRENT VS 5Y AVG
+86.92%
CURRENT VS 10Y AVG
+85.65%
CURRENT VS 15Y AVG
+80.18%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+86.91%
vs the sector median at left
MacroGenics, Inc.
Market Cap
$231.69M
Return on Assets (ROA)
-4.22%
TTM Avg
-27.32%
3Y Avg
-24.76%
5Y Avg
-32.27%
Market Cap
$230.51M
Return on Assets (ROA)
-29.12%
TTM Avg
-42.23%
3Y Avg
-51.88%
5Y Avg
-48.35%
Market Cap
$234.79M
Return on Assets (ROA)
-34.55%
TTM Avg
-30.02%
3Y Avg
-24.36%
5Y Avg
-21.40%
Market Cap
$235.67M
Return on Assets (ROA)
-23.88%
TTM Avg
-71.64%
3Y Avg
-51.89%
5Y Avg
-47.09%
Market Cap
$234.90M
Return on Assets (ROA)
-1.57%
TTM Avg
17.43%
3Y Avg
19.75%
5Y Avg
24.82%
Market Cap
$236.06M
Return on Assets (ROA)
-23.80%
TTM Avg
-23.59%
3Y Avg
-108.30%
5Y Avg
-108.30%
Market Cap
$236.03M
Return on Assets (ROA)
8.42%
TTM Avg
10.27%
3Y Avg
11.53%
5Y Avg
11.43%
Market Cap
$235.32M
Return on Assets (ROA)
-114.79%
TTM Avg
-67.19%
3Y Avg
-63.94%
5Y Avg
-45.91%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MacroGenics, Inc. (MGNX) | $231.69M | -4.22% | -27.32% | -24.76% | -32.27% |
| Biodesix, Inc. (BDSX)vs › | $230.51M | -29.12% | -42.23% | -51.88% | -48.35% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $234.79M | -34.55% | -30.02% | -24.36% | -21.40% |
| InflaRx N.V. (IFRX)vs › | $235.67M | -23.88% | -71.64% | -51.89% | -47.09% |
| Vogenx Inc. (VOGX)vs › | $227.77M | N/A | N/A | N/A | N/A |
| SIGA Technologies, Inc. (SIGA)vs › | $234.90M | -1.57% | 17.43% | 19.75% | 24.82% |
| BioAge Labs Inc. (BIOA)vs › | $236.06M | -23.80% | -23.59% | -108.30% | -108.30% |
| Utah Medical Products, Inc. (UTMD)vs › | $236.03M | 8.42% | 10.27% | 11.53% | 11.43% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $235.32M | -114.79% | -67.19% | -63.94% | -45.91% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $237.35M | -8.48% | -16.43% | -20.20% | -32.31% |
ROA
-4.2%
ROE
-34.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -29.05% |
| 2024-12-31 | -25.59% |
| 2023-12-31 | -3.04% |
| 2022-12-31 | -41.37% |
| 2021-12-31 | -60.29% |
| 2020-12-31 | -34.26% |
| 2019-12-31 | -48.58% |
| 2018-12-31 | -51.62% |
| 2017-12-31 | -5.25% |
| 2016-12-31 | -18.80% |
| 2015-12-31 | -5.61% |
| 2014-12-31 | -22.03% |
| 2013-12-31 | -0.21% |
| 2012-12-31 | 15.56% |
| 2011-12-31 | 10.72% |
